Lawrence A. Leiter

MDCM, FRCPC, FACP, FACE, FAHA

Investigator

Biography

Please note: Dr. Leiter is not taking any summer students.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 750 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas. In 2018, 2019, and 2020 he was a Clarivate Analytics Top 1% Highly Cited Researcher

Dr. Leiter is a past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Distinguished Service Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.  In 2019 was elected as a Fellow of the Canadian Academy of Health Sciences

Recent Publications

  1. Kolkailah, AA, Wiviott, SD, Raz, I, Murphy, SA, Mosenzon, O, Bhatt, DL et al.. Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. Diabetes Care. 2022;45 (2):e27-e29. doi: 10.2337/dc21-1668. PubMed PMID:35020832 .
  2. Cahn, A, Wiviott, SD, Mosenzon, O, Goodrich, EL, Murphy, SA, Yanuv, I et al.. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care. 2022; :. doi: 10.2337/dc21-1744. PubMed PMID:35015847 .
  3. Pitt, B, Steg, G, Leiter, LA, Bhatt, DL. Response to the Letter on "The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus". Cardiovasc Drugs Ther. 2022; :. doi: 10.1007/s10557-021-07309-5. PubMed PMID:35006530 .
  4. Raubenheimer, PJ, Cushman, WC, Avezum, A, Basile, J, Conget, I, Dagenais, G et al.. Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial. Diabetes Obes Metab. 2022; :. doi: 10.1111/dom.14634. PubMed PMID:34984808 .
  5. Leiter, LA, Banach, M, Catapano, AL, Duell, PB, Gotto, AM Jr, Laufs, U et al.. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab. 2022; :. doi: 10.1111/dom.14645. PubMed PMID:34981622 .
  6. Pitt, B, Steg, G, Leiter, LA, Bhatt, DL. Correction to: The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovasc Drugs Ther. 2021; :. doi: 10.1007/s10557-021-07308-6. PubMed PMID:34950964 .
  7. Abtan, J, Bhatt, DL, Held, C, Simon, T, Fox, K, Mehta, SR et al.. Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. Circ Cardiovasc Interv. 2021;14 (12):e011035. doi: 10.1161/CIRCINTERVENTIONS.120.011035. PubMed PMID:34814698 .
  8. Pitt, B, Steg, G, Leiter, LA, Bhatt, DL. The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovasc Drugs Ther. 2021; :. doi: 10.1007/s10557-021-07291-y. PubMed PMID:34750713 .
  9. Higgins, V, Leiter, LA, Delaney, SR, Beriault, DR. Validating the NIH LDL-C equation in a specialized lipid cohort: Does it add up?. Clin Biochem. 2022;99 :60-68. doi: 10.1016/j.clinbiochem.2021.10.003. PubMed PMID:34656564 .
  10. Pieber, TR, Bajaj, HS, Heller, SR, Jia, T, Khunti, K, Klonoff, DC et al.. Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial. Diabetes Obes Metab. 2022;24 (2):332-336. doi: 10.1111/dom.14564. PubMed PMID:34605127 .
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto
X